Advanced Search

 

Study ID Status Title Patient Level Data
208141/023 Completed A double-blind study to compare between groups, in healthy HSV-seronegative adolescent subjects, the humoral and cellular immune response and the reactogenicity of herpes simplex candidate vaccines containing gD (10µg or 20µg) and 2 doses of Al-MPL.
208141/024 Completed A double blind, randomized trial comparing the immunogenicity of 3 commercial scale consistency lots of gD-Alum-MPL vaccine containing CHO K1 gD in healthy HSV seronegative adult subjects.
208141/026 Completed Study comparing different doses and schedules of GSK Bio's candidate prophylactic herpes simplex virus vaccine (gD-AS04) in healthy HSV- subjects aged 10-15 and 16-18 yrs to healthy HSV- adults (aged 19-45 yrs) receiving the vaccine on a 0-1-6 mth schedule.
208141/037 Completed Open study to further evaluate the safety and reactogenicity of GlaxoSmithKline Biologicals’ prophylactic herpes simplex candidate vaccine with gD-alum-MPL in HSV-1 and HSV-2 seronegative (HSV 1-/2-) women who previously received either alum-MPL or alum as placebo during one of GlaxoSmithKline Biologicals’ phase III studies 208141/005 (HSV-007), 208141/016 (HSV-016) or 208141/017 (HSV-017) Study Listed on ClinicalStudyDataRequest.com
208141/038 Completed Open study to further evaluate the safety, reactogenicity, and immunogenicity of GlaxoSmithKline Biologicals’ prophylactic herpes simplex candidate vaccine with gD-alum-MPL in HSV-1 and HSV-2 seronegative (HSV 1-/2-) women who previously received either alum-MPL or alum as placebo during one of GlaxoSmithKline Biologicals’ Phase III studies 208141/005 (HSV-007), 208141/016 (HSV-016) or 208141/017 (HSV-017) Study Listed on ClinicalStudyDataRequest.com
208141/039 Completed A study to assess the prophylactic efficacy and safety of gD-Alum/MPL vaccine in the prevention of genital herpes disease in young women who are HSV-1 and -2 seronegative.
208141/040 Completed A study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals' herpes simplex candidate vaccine (gD2‑AS04) in healthy HSV seronegative and seropositive female subjects aged 10-17 years. Study Listed on ClinicalStudyDataRequest.com
208141/041 Completed Extension to study comparing doses and schedules of GSK's candidate prophylactic herpes simplex virus vaccine (gD-AS04) in healthy HSV- subjects aged 10-15 and 16-18 yrs to healthy HSV- adults (aged 19-45 yrs) receiving the vaccine on a 0-1-6 mth schedule. Study Listed on ClinicalStudyDataRequest.com
208141/042 Completed A Phase III, double-blind, randomized, study to compare: 1) the immunogenicity and safety of 3 commercial scale consistency lots of GlaxoSmithKline (GSK) Biologicals’ herpes simplex candidate vaccine in healthy HSV-1 and -2 seronegative (HSV 1-/2-) female subjects aged 10 – 17 years, and 2) vaccine immunogenicity in healthy HSV 1-/2- females aged 10 – 17 years with healthy HSV 1-/2- adult females Study Listed on ClinicalStudyDataRequest.com
208144/001 Completed A phase III, open study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Mencevax™ ACW135Y vaccine when administered as a single dose to healthy subjects aged 2-30 years.
208144/002 Completed Multicentric, Surveillance Study to Monitor Safety of GSK Biologicals' Purified Meningococcal Polysaccharide Vaccine of Serogroups ACWY in 3,000 Filipino Subjects Aged above 2 Years When Administered According to the Prescribing Information.
208355/022 Completed Double-blind randomised comparative assessment of the immunogenicity and reactogenicity of 3 different lots of SB Bios´ combined diphtheria, tetanus, acellular pertussis vaccine.The vaccine will be admin to healthy infants as a primary vaccination course of 3 consecutive doses at 3-4-5 months of age
208355/050 Completed Prospective Household Contact Study to compare the frequency of clinical pertussis disease following household exposure in children previously vaccinated with a primary course of 3 doses of SB Biologicals combined acellular tricomponent DTPa vaccine and in children not immunized against pertussis
208355/101 Completed Comparative assessment of immunogenicity and reactogenicity of three different production lots of SB Biologicals combined diphtheria, tetanus, tricomponent acellular (PT 25 g + FHA 25 g + PRN 8 g) vaccine administered as a booster dose in healthy 15 to 24 month old children
208355/117 Completed A study of the safety and immunogenicity of initiating a primary vaccination series of DTPa administered at 2, 4, and 6 months of age with Tripedia® and completing the series with Infanrix®
208355/118 Completed Comparative assessment of immunogenicity and reactogenicity of three different production lots of SB Biologicals combined diphtheria, tetanus, tricomponent acellular (PT 25 g + FHA 25 g + PRN 8 g) vaccine administered as a booster dose in healthy 15 to 24 month old children
208355/120 Completed Clinical study of the reactogenicity and immunogenicity of SB Biologicals’ DTPa vaccine administered as a booster to healthy children 4 to 6 years of age, previously vaccinated with four doses of SB Biologicals’ DTPa vaccine in the first two years of life
208355/122 Completed Open prospective clinical study to assess the reactogenicity and immunogenicity of SB Biologicals’ APV vaccine administered as a booster dose to healthy children of 10-11 years of age (11 years included) previously primed with three doses of DTP whole cell vaccine.
208355/123 Completed A phase III, open, multicenter study of the safety and immunogenicity of a booster dose of SmithKline Beecham Biologicals’ Diphtheria and Tetanus toxoids and acellular Pertussis (DTaP) vaccine (Infanrix™) and Pasteur Mérieux’s Haemophilus influenzae type b (Hib) conjugate vaccine (OmniHIB®) when administered intramuscularly as separate injections between 12 and 18 months of age following primary immunization at 2 months, 4 months, and 6 months of age in study DTPa-HBV-IPV-027 (217744/027) Study Listed on ClinicalStudyDataRequest.com
208355/124 Completed An open, 3.5 year, immunogenicity follow-up of subjects who previously received GSK Biologicals’ dTpa vaccine or GSK Biologicals’ DTPa vaccine or Chiron Behring’s Td vaccine + either Pasteur Merieux’s Pa vaccine or GSK Biologicals’ pa vaccine, administered as a booster dose at age 4-6 years in study 208355/118 (APV-118) Study Listed on ClinicalStudyDataRequest.com
208355/125 Completed A phase III, open, multicenter study of the safety of Infanrix® when administered as a booster dose at 15 to 18 months of age following primary immunization in studies 217744/084 and 217744/085 (Subjects from DTaP-HepB-IPV-084 and DTaP-HepB-IPV-085) Study Listed on ClinicalStudyDataRequest.com
208355/128 Completed Evaluation of safety and efficacy through Post Market Surveillance for Infanrix™, the DTaP mixed vaccine Study Listed on ClinicalStudyDataRequest.com
209762/136 Completed A phase III, blinded, randomized, multicenter U.S. study evaluating the clinical consistency of three production lots of SmithKline Beecham Biologicals' MMR vaccine (PRIORIX) and comparability of PRIORIX with Merck's M-M-R II vaccine, administered to healthy children 12 to 18 months of age Study Listed on ClinicalStudyDataRequest.com
209762/146 Completed Open, multicentre study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals live attenuated Measles-Mumps-Rubella vaccine (Priorix) given to healthy children at the age of 12 to 15 months or 4- 6 years
209762/147 Completed Phase IV open study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ live attenuated Measles-Mumps-Rubella (MMR) vaccine when given to healthy children at the age of 12 to 18 months in Singapore. Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.